deltatrials
Completed PHASE4 INTERVENTIONAL 2-arm NCT03885713

Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease (BioIBD)

Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease by Proteomic and Mass Cytometry Approaches

Sponsor: Fundación de Investigación Biomédica - Hospital Universitario de La Princesa

Conditions Crohn Disease Inflammatory Bowel Diseases Ulcerative Colitis
Interventions Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab or tofacitinib
Updated 13 times since 2019 Last updated: Mar 12, 2025 Started: Sep 10, 2019 Primary completion: Dec 31, 2024 Completion: Dec 31, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03885713, this PHASE4 trial focuses on Crohn Disease and Inflammatory Bowel Diseases and remains completed. Sponsored by Fundación de Investigación Biomédica - Hospital Universitario de La Princesa, it has been updated 13 times since 2019, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Apr 2019 – ~Sep 2019 · 5 months · monthly snapshot~Sep 2019 – ~Nov 2019 · 2 months · monthly snapshot~Nov 2019 – ~Jun 2020 · 7 months · monthly snapshot~Jun 2020 – ~Jan 2021 · 7 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Apr 2022 · 7 months · monthly snapshot~Apr 2022 – ~Oct 2023 · 18 months · monthly snapshot~Oct 2023 – ~Dec 2023 · 2 months · monthly snapshot~Dec 2023 – ~Jul 2024 · 7 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Apr 2025 · 7 months · monthly snapshot~Apr 2025 – ~Sep 2025 · 5 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

13 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE4

  2. Apr 2025 — Sep 2025 [monthly]

    Completed PHASE4

    Status: Recruiting → Completed

  3. Sep 2024 — Apr 2025 [monthly]

    Recruiting PHASE4

  4. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE4

  5. Dec 2023 — Jul 2024 [monthly]

    Recruiting PHASE4

▶ Show 8 earlier versions

  1. Oct 2023 — Dec 2023 [monthly]

    Recruiting PHASE4

  2. Apr 2022 — Oct 2023 [monthly]

    Recruiting PHASE4

  3. Sep 2021 — Apr 2022 [monthly]

    Recruiting PHASE4

  4. Jan 2021 — Sep 2021 [monthly]

    Recruiting PHASE4

  5. Jun 2020 — Jan 2021 [monthly]

    Recruiting PHASE4

  6. Nov 2019 — Jun 2020 [monthly]

    Recruiting PHASE4

    Status: Not Yet Recruiting → Recruiting

  7. Sep 2019 — Nov 2019 [monthly]

    Not Yet Recruiting PHASE4

  8. Apr 2019 — Sep 2019 [monthly]

    Not Yet Recruiting PHASE4

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Data source: Fundación de Investigación Biomédica - Hospital Universitario de La Princesa

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alicante, Spain , Córdoba, Spain , Donostia / San Sebastian, Spain , Fuenlabrada, Spain , Galdakao, Spain , Girona, Spain , Huelva, Spain , Huesca, Spain , Madrid, Spain , Oviedo, Spain and 9 more locations